Target
$156.18 → $156.12
Current stock research snapshot · 7/31/26 26 days old
IRTCiRhythm
Investment conviction●●○○○2 of 5 · current snapshot
Research target$156.12Current stock price target
Investment thesis statusSTRENGTHENEDLast reviewed 7/31/26
Market cap$4.02BSnapshot value · 7/31/26
Research history
See all IRTC changes ↗What changed
Thesis status
NEEDS_MORE_DATA → STRENGTHENED
Target
$156.19 → $156.18
Healthspan taxonomy seed — see taxonomy_path
iRhythm Zio monitor adoption; Q2 2026 earnings; Medicare reimbursement expansion; AI-based arrhythmia detection improvements
Thesis breaks if restrictive final LCDs on ambulatory cardiac monitoring are adopted (Medicare ~24% of revenue), reimbursement concentration (83% payor) sees CMS/CPT rate cuts, or cybersecurity class actions (June 2026) escalate. (vault 2026-08)
Bullish — New position in PFM Health Q2 13F; increased in Eagle Health. [X search Aug 2026]
Snapshot · 7/31/26🟡 Mixed · ins-$7.9M · 13F 18+/6-×0.5 · short↑0.4
Snapshot · 7/31/26Timestamped research update
Deep research update
382 words · Updated Aug 22, 2026
Research in development: this latest 382-word update is published for context while it is expanded toward the 1,000-word editorial standard.
iRhythm (renamed iRhythm Holdings, Inc. in the 2026 holdco reorganization) is the leading AI-enabled ambulatory cardiac monitoring service — Zio XT/Zio AT wearable patches (14-day continuous ECG) + FDA-cleared deep-learned interpretation + Medicare-enrolled IDTF billing, sold through prescribing physicians and health systems. Acquiring VitalConnect (VitalPatch) for $287.5M to expand into multi-vital-sign remote patient monitoring.
Q2 2026 revenue $224.17M (+20.1% YoY); H1 2026 $423.56M (+22.6%); FY2025 $747.14M. Gross margin 72.8% (Q2-26), up from 70.6% (FY25). Operating loss narrowed to −$2.54M (Q2-26) — near breakeven. Market cap ~$4.23B.
healthspan "Maintain" picks-and-shovels — the AI diagnostic + reimbursed monitoring network that catches arrhythmias before stroke/hospitalization, with data-flywheel economics that widen GM as volume scales.
- Q2 2026 revenue $224.17M +20.1% YoY; GM 72.8% (+220 bps YoY) — companyfacts / 10-Q (2026-06-30).
- Net loss narrowed to −$0.38M (Q2-26) from −$14.22M (Q2-25) — breakeven crossing.
- Baxter Settlement (7/31/26): $50.0M to clear ALL BardyDx/Welch Allyn/Baxter patent litigation + worldwide royalty-free cross-license + 6-yr covenant not to sue — 10-Q Note 12.
- VitalConnect acquisition (8/5/26): $287.5M ($237.5M cash + $50M stock), close by end 2026 — 10-Q Note 12 / 8-K.
- 83% of FY2025 revenue third-party-payor reimbursed, 24% Medicare — 10-K.
- 135+ research manuscripts; CAMELOT (287,789 Medicare lives) + AVALON (428,707 insured) studies — 10-K.
the deep-learned AI interpretation engine + the largest continuous-ECG training corpus + 15 years of peer-reviewed clinical evidence + IDTF reimbursement infrastructure. Hardware is replicable; the data + evidence + reimbursement flywheel is not.
- Proposed 2025 LCDs (Noridian/Palmetto/CGS) could restrict Medicare coverage (~24% of revenue) if finalized restrictively.
- 83% payor-reimbursed = direct exposure to CMS/CPT rate changes.
- June 2026 cybersecurity incident → 3 class actions (impact unestimable).
- $651M convertible notes + $50M stock deal component = dilution overhang.
- VitalConnect's revenue/run-rate (private, undisclosed) → the EV/revenue multiple of the $287.5M deal cannot yet be computed.
- Final status of the Sept 2025 proposed LCDs (not yet adopted as of the 8/6/26 10-Q) — needs CMS/MAC tracking.
- Whether the dense May–Aug 2026 insider Form 4 sales are 10b5-1 (diversification) or discretionary (thesis signal).
STRENGTHENED.